Walgreens taps Bazaarvoice for social commerce platform
AUSTIN, Texas Walgreens has selected Bazaarvoice’s social commerce suite to optimize its customers’ experience, Bazaarvoice announced Monday.
Walgreens will utilize Bazaarvoice’s SearchVoice Inline, which makes customer reviews readily available on leading search engines, maximizing SEO results and ensuring that customers can find the right product and better engage purchase-ready consumers at every step of the shopping process, Bazaarvoice said. Additionally, the drug store chain also will use measurable social commerce, as well as the ability to receive reviews from a world-class network of manufacturers using Bazaarvoice’s BrandVoice solution.
“We’re honored to welcome Walgreens as one of our newest clients,” said Brett Hurt, founder and CEO of Bazaarvoice. “We look forward to becoming Walgreens’ long-term partner as it leverages reviews to further advance its social commerce strategy and drive value across the entire company. This is the core of our multichannel value proposition to our clients.”
Big Y finalizing purchase of Conn.-based A&P stores
SPRINGFIELD, Mass. Big Y reportedly is closing its deal to acquire seven A&P stores in northern Connecticut.
The Springfield, Mass.-based retailer said the sale will be completed on Nov. 1, according to the Boston Herald. Big Y owns stores in Massachusetts and Connecticut and has served these markets for nearly 75 years.
As previously reported by Drug Store News, grocer A&P announced in September an agreement with Big Y to sell the stores as part of its turnaround strategy.
“We continue to evaluate our operating footprint and its alignment with our turnaround strategy. These seven stores were clearly outside of our core markets, and their sale was necessary,” Sam Martin, president and CEO of A&P, stated at the time.
NeurogesX seeks expanded approval for Qutenza
SAN MATEO, Calif. A company that develops drugs for pain is hoping to get approval of one of its drugs for a pain condition associated with HIV.
NeurogesX announced Monday that it would seek Food and Drug Administration approval for the drug Qutenza (capsaicin) as a treatment for HIV-associated neuropathy, also called HIV-AN or HIV-distal sensory polyneuropathy, in the first half of 2011. The drug, a patch, already is approved for post-herpetic neuralgia. HIV-AN results from injury to sensory neurons by HIV virus proteins, the body’s immune response to the virus and some drugs used to treat it.
“As a company, we are focused on addressing unmet medical needs in pain and have made significant progress toward this goal with the U.S. launch of Qutenza,” NeurogesX president and CEO Anthony DiTonno said. “Our decision to submit a supplemental [application] to address the HIV-AN patient population is important as there are currently no FDA-approved treatments for HIV-AN.”